Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core US Aggregate Bond ETF (AGG) vs Pfizer Inc (PFE) Price & Performance

iShares Core US Aggregate Bond ETFTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

iShares Core US Aggregate Bond ETF vs Pfizer Inc — how do they compare? iShares Core US Aggregate Bond ETF trades at $97.33, while Pfizer Inc trades at $26.58 (market cap $154.18B). The key difference: Pfizer Inc pays a 6.36% dividend while iShares Core US Aggregate Bond ETF pays none, and Pfizer Inc is trading nearer its 52-week high, iShares Core US Aggregate Bond ETF nearer its low. Which is the better fit depends on your goals.

AGGPFE
Sector
Fixed IncomeHealth
52-Week High
$101.40$28.56
52-Week Low
$97.24$23.60
Market Cap
$154.18B
Volume
29,869,932
Enterprise Value
$205.67B
Dividend Yield
6.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core US Aggregate Bond ETF

AGG trades at $97.6, up 0.17% on the day, with a neutral technical signal and bearish moving averages. Recent news highlights institutional accumulation and bond ETF inflows amid fluctuating Treasury yields. The ETF offers consistent dividends, with the latest payments scheduled for 2026.

Outlook remains tied to interest rate trends and inflation data, presenting income stability but facing pressure from rising yields. Key risks include Fed policy shifts and geopolitical impacts on oil prices, while institutional buying signals confidence in fixed-income appeal.

Pfizer Inc

Pfizer (PFE) trades at $26.74, up 2.06% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. Recent quarters show consistent earnings beats, though revenue has moderated from pandemic peaks. The company maintains a strong cash position of $20.48 billion (2024) and a dividend yield supported by a $0.43 per share payout. Key developments include a focus on obesity and oncology pipelines, with several catalysts expected in 2026.

The outlook balances a stable dividend and pipeline potential against post-COVID revenue normalization and patent cliff risks. Near-term upside exists if pipeline catalysts materialize, but investors face headwinds from competitive pressures and projected net income margin compression to 6.8% in 2026. The stock's valuation at a P/E of 35.21 appears elevated relative to earnings growth, warranting caution despite technical strength.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Core US Aggregate Bond ETF

AGG tracks the Bloomberg U.S. Aggregate Bond Index, providing broad exposure to the total U.S. investment-grade bond market. It serves as a core portfolio building block by diversifying across Treasuries, government-related bonds, corporate debt, and mortgage-backed securities.

Read more on AGG

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE